However, responses in humans to mTOR inhibitors, namely for fibrofolliculomas, were not seen [211], suggesting that alternative oncogenic pathways exist beyond mTOR activation in FLCN-deficient tumors. Here, MTOR is linked to Fibrofolliculoma.